ACAD
19.36
-0.93
-4.58%
AEMD
4.9
-1.1
-18.33%
APRI
1.17
-0.03
-2.50%
ARNA
1.57
-0.04
-2.48%
ATEC
0.4
+0.01
+1.32%
CNAT
1.84
-0.01
-0.54%
CRXM
0.25
0.00
0.00%
CYTX
0.179
-0.011
-5.6345%
DXCM
61.98
-8.65
-12.25%
GNMK
5.08
-0.42
-7.64%
HALO
7.9
-0.37
-4.47%
ILMN
136.05
-7.33
-5.11%
INNV
0.038
-0.002
-5.2500%
INO
6.01
-0.25
-3.99%
ISCO
2.4
+0.13
+5.73%
ISIS
57.56
0.00
0.00%
LGND
92.5
-6.44
-6.51%
LPTN
0.16
-0.015
-8.5143%
MBVX
0.54
-0.02
-3.55%
MEIP
1.24
0.00
0.00%
MNOV
4.15
-0.14
-3.26%
MRTX
20.26
-1.1
-5.15%
MSTX
0.41
+0.01
+2.4506%
NBIX
35.99
-1.08
-2.91%
NUVA
41.45
-2.98
-6.71%
ONCS
1.69
-0.01
-0.59%
ONVO
2.09
-0.21
-9.13%
OREX
1.84
-0.05
-2.65%
OTIC
13.8
-0.25
-1.78%
QDEL
16.4
-0.49
-2.90%
RCPT
231.96
0.00
0.00%
RGLS
5.94
-0.41
-6.46%
RMD
57.42
-0.4
-0.69%
SCIE
0.001
0.00
+11.111%
SPHS
1.68
-0.09
-5.08%
SRNE
5.05
+0.04
+0.80%
TROV
3.85
-0.13
-3.27%
VICL
0.333
-0.007
-1.9741%
VOLC
18
0.00
0.00%
ZGNX
8.49
-0.41
-4.61%
ACAD
19.36
-0.93
-4.58%
AEMD
4.9
-1.1
-18.33%
APRI
1.17
-0.03
-2.50%
ARNA
1.57
-0.04
-2.48%
ATEC
0.4
+0.01
+1.32%
CNAT
1.84
-0.01
-0.54%
CRXM
0.25
0.00
0.00%
CYTX
0.179
-0.011
-5.6345%
DXCM
61.98
-8.65
-12.25%
GNMK
5.08
-0.42
-7.64%
HALO
7.9
-0.37
-4.47%
ILMN
136.05
-7.33
-5.11%
INNV
0.038
-0.002
-5.2500%
INO
6.01
-0.25
-3.99%
ISCO
2.4
+0.13
+5.73%
ISIS
57.56
0.00
0.00%
LGND
92.5
-6.44
-6.51%
LPTN
0.16
-0.015
-8.5143%
MBVX
0.54
-0.02
-3.55%
MEIP
1.24
0.00
0.00%
MNOV
4.15
-0.14
-3.26%
MRTX
20.26
-1.1
-5.15%
MSTX
0.41
+0.01
+2.4506%
NBIX
35.99
-1.08
-2.91%
NUVA
41.45
-2.98
-6.71%
ONCS
1.69
-0.01
-0.59%
ONVO
2.09
-0.21
-9.13%
OREX
1.84
-0.05
-2.65%
OTIC
13.8
-0.25
-1.78%
QDEL
16.4
-0.49
-2.90%
RCPT
231.96
0.00
0.00%
RGLS
5.94
-0.41
-6.46%
RMD
57.42
-0.4
-0.69%
SCIE
0.001
0.00
+11.111%
SPHS
1.68
-0.09
-5.08%
SRNE
5.05
+0.04
+0.80%
TROV
3.85
-0.13
-3.27%
VICL
0.333
-0.007
-1.9741%
VOLC
18
0.00
0.00%
ZGNX
8.49
-0.41
-4.61%
Home » Archive by Category

Syndication

Market Development Manager – Oncology – Illumina, Inc. – San Diego, CA

November 26, 2015 – 12:27 am

Our customers include a broad range of academic, government, pharmaceutical, biotechnology, and other leading institutions around the globe….
From Illumina, Inc. – 26 Nov 2015 07:27:27 GMT
– View all San Diego jobs

Sr Manager, Engineering – Illumina, Inc. – San Diego, CA

November 26, 2015 – 12:27 am

Our customers include a broad range of academic, government, pharmaceutical, biotechnology, and other leading institutions around the globe. All About Us:….
From Illumina, Inc. – 26 Nov 2015 07:27:14 GMT
– View all San Diego …

Research/Production Associate (Mira Mesa)

November 25, 2015 – 5:27 pm

CTK Biotech is a San Diego based company that develops and manufactures diagnostic test kits. We are looking for candidates with training and experience in development and production of recombinant proteins and antibodies. Extensive hands-on experien […

(Associate)Production Manager (Mira Mesa)

November 25, 2015 – 5:23 pm

Position Summary
Adherent to the ISO Quality Management System, organize and participate in the production of antibody and recombinant antigens according to established procedures. Manage production priority through communication with other departme […

Data Migration Lead (Bio / Full-Time) (Sorrento Valley)

November 25, 2015 – 2:10 pm

Data Migration Lead (Bio / Full-Time)
A San Diego Biotech company is looking for a Data Migration Lead. The Data Migration Lead plays a central and key role within the company’s growing product catalog and operational databases. This position is pri […

Associate Director, Clinical Data Management – Intercept Pharmaceuticals – San Diego, CA

November 25, 2015 – 1:38 pm

Job Descriptions: POSITION SUMMARY: The Senior Clinical Data Manager coordinates and completes data management activities to ensure accuracy and consistency
From Intercept Pharmaceuticals – 25 Nov 2015 20:38:08 GMT
– View all S…

GenomeDx’s Decipher® Test and Decipher GRID(TM) to be Featured in Five Presentations at Society of Urologic Oncology

November 25, 2015 – 1:30 pm

SAN DIEGO, Nov. 25, 2015 /PRNewswire/ — GenomeDx Biosciences today announced that data from several of its programs will be presented at the Society of Urologic Oncology’s 16th Annual Meeting, held Dec. 2-4 in Washington, D.C. Five presentations will highlight data from the Decipher® Prostate Cancer Classifier, Decipher Genomic Resource Information Database (Decipher GRID™) and the company’s research on bladder cancer.

Wednesday, Dec. 2
Session I: 4:30 p.m. to 6 p.m. EST

Title: Validation of a Genomic Classifier for prediction of metastasis following postoperative salvage radiation therapy
Presenter: Robert Den, M.D., assistant professor of radiation oncology and cancer biology at Thomas Jefferson University
Poster Number: 74

Title: Validation of a Genomic Classifier for predicting post-prostatectomy recurrence in a community based health care setting
Poster Number: 78

Title: Efficacy of early and delayed radiation in a prostatectomy cohort adjusted for genomic and clinical risk
Presenter: Ashley Ross, M.D., Ph.D., associate professor of urology and oncology, Johns Hopkins School of Medicine
Poster Number: 106

Title: B7H3 expression is androgen related and predictive of prostate cancer outcomes in a large natural history cohort of men undergoing prostatectomy
Presenter: Ashley Ross, M.D., Ph.D., associate professor of urology and oncology, Johns Hopkins School of Medicine
Poster Number: 105

Friday, Dec. 4
Young Urologic Oncologists Program: 4:30 p.m. to 6 p.m. EST

Title: Can bladder cancer gene expression signatures be used to predict lymph node metastasis at the time of radical cystectomy?
Presenter: Roland Seiler, M.D., University of British Columbia
Presentation Number: 1

About Decipher® Prostate Cancer Classifier
Decipher® is a genomic test that provides an assessment of tumor aggressiveness and is used by radiation oncologists and urologists to determine who to treat and how to treat them in order to offer the most effective and least harmful course of therapy. Decipher offers valuable insight that is distinct from clinical measures of risk including PSA and Gleason score. Studies of thousands of patients from leading cancer centers, published in more than 20 peer-reviewed journals, demonstrate that Decipher can accurately predict metastatic disease, identify patients most likely to benefit from therapeutic intervention, and lead to significant cost-savings for healthcare systems by reducing unnecessary procedures. Decipher is covered by Medicare and multiple private insurance plans in the US representing over 190 million covered lives.

Learn more at www.DecipherTest.com 

About Decipher GRIDTM
The Decipher Genomic Resource Information Database (Decipher GRID™) is the world’s largest clinically-annotated genomic expression database in urologic cancer created to enable improvements to precision medicine in patient care. GRID unifies a patient’s whole genome data with clinical outcomes from thousands of patients evaluated with Decipher®, providing unprecedented data sharing capabilities. Ultimately, GRID will use patient tumor genomic information to better match an individual to a targeted therapy with the highest likelihood of providing a benefit. The Decipher GRID program is rapidly expanding as major cancer centers partner with GenomeDx to access the database to advance their understanding of urologic cancers through the analysis of large amounts of genomic data.

Learn more at www.DecipherGRID.com

About GenomeDx Biosciences
GenomeDx Biosciences is a genomic information company changing the landscape of urologic cancer patient care with innovative genomic solutions that empower physicians and patients to make more informed decisions about patient treatment. Using advanced cloud-based bioinformatics to mine vast amounts of genomic data, the company develops and commercializes proprietary clinical tests that provide actionable information to answer key clinical questions in patient management. GenomeDx’s Decipher® is a genomic test that provides an assessment of tumor aggressiveness and is used by urologists and radiation oncologists to determine who to treat and how to treat them in order to offer the most effective and least harmful course of therapy. In partnership with leading medical centers, GenomeDx is building Decipher GRID, the world’s largest clinically-annotated genomic expression database in urologic cancer created to enable improvements to precision medicine in patient care. GenomeDx is based in San Diego and Vancouver, British Columbia.

Learn more at www.GenomeDx.com

Media Contact:
Ian Stone
Canale Communications
619-849-5388
ian@canalecomm.com

 

SOURCE GenomeDx Biosciences

The Salk Institute for Biological Studies – GLASSWASHER (E961) (La Jolla)

November 25, 2015 – 1:25 pm

The Salk Institute for Biological Studies is one of the world’s preeminent basic research institutions, where internationally renowned faculty probe fundamental life science questions in a unique, collaborative, and creative environment. Focused on b […

Sr. Equipment & Facilities Assistant – Ajinomoto Althea, Inc. – San Diego, CA

November 25, 2015 – 1:01 pm

Is a fully integrated contract development and manufacturing organization providing clinical drug process development and manufacturing services to global…
From Ajinomoto Althea, Inc. – 25 Nov 2015 20:01:42 GMT
– View all San…

Neurocrine Biosciences to Present at the 27th Annual Piper Jaffray Healthcare Conference

November 25, 2015 – 11:00 am

Live Audio Webcast will be on December 2, 2015

SAN DIEGO, Nov. 25, 2015 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the 27th Annual Piper Jaffray Healthcare Conference in New York.

The live presentation takes place on Wednesday, December 2 at 11:00am ET (8:00am PT).  The presentation will be webcast and may be accessed on the Company’s website at http://www.neurocrine.com.  

Listeners are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software.  A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders.  The Company’s two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone antagonist for women’s health that is partnered with AbbVie Inc., and NBI-98854, a vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders.  Neurocrine intends to maintain certain commercial rights to its VMAT2 inhibitor for evolution into a fully-integrated pharmaceutical company. 

Neurocrine Biosciences, Inc. news releases are available through the Company’s website via the internet at http://www.neurocrine.com.

 

SOURCE Neurocrine Biosciences, Inc.